Acute attack management

AuraSTOP in the acute phase

In the context of the overall management of individuals with migraines, the use of the formulation can be taken into account in forms of mild or moderate intensity. It can represent an option to be evaluated in particular patients younger than 18 years and older than 65 years, groups of the population in which it is often appropriate to take a prudent approach in the choice of targeted approaches. Furthermore, in chronic forms of migraine, it can be considered as part of an overall strategy aimed at promoting the reduction of frequent analgesic intake, helping to limit the risk of medication overuse of the usual drug treatments.

In patients with tension-type headache, use can be evaluated as a support in the management of episodes, within a broader approach, which also takes into account any triggering factors, lifestyle and physical and psychological stress conditions. In any situation, it is advisable that the choice be made with the support of the doctor, who will be able to evaluate the overall clinical picture and the appropriateness of use, on a case-by-case basis.

Usual approaches for Migraine Attacks

In the event of a migraine attacks, the drug options are selected by the doctor based on the patient’s clinical characteristics, the severity of the episode, the therapeutic history and the presence of any contraindications. One of the treatment options is the use of triptans, to be taken as early as possible at the beginning of the attack. In the event of an unsatisfactory response, analgesics can be used, including ibuprofen or indomethacin, and in any case always according to medical indication.

Both classes have limitations of use. Triptans are contraindicated in subjects under the age of 18 or over 65 and in patients with cerebrovascular diseases or uncontrolled arterial hypertension. Analgesics, on the other hand, require caution or are contraindicated in the presence of gastric, kidney or liver failure; Furthermore, they are not indicated in pediatric age or in elderly patients. They should also be avoided in subjects with bleeding diathesis or in concomitant treatment with anticoagulant or antiplatelet drugs.